- 24 Tech Roqad st Ny 10023
- editech@mail.com
Leadership Team
Executive Leadership Team
The Executive Leadership Team steers operational excellence and strategic execution across Cohance’s global footprint. With extensive experience spanning life sciences, the pharmaceutical sector, and the CDMO industry—including regulatory compliance and business scaling—they lead with agility, vision, and purpose.
Vivek Sharma
Executive Chairman
Dr. V. Prasada Raju
Managing Director
Sudhir Kumar Singh
Chief Executive Officer
Gaurav Bahadur
Chief Human Resources Officer
Himanshu Agarwal
Chief Financial Officer
K. Nagendra Babu
Chief Quality and Compliance Officer
Nitin Kumar
Chief Information Officer
K. Nagendra Babu
Chief Quality and Compliance Officer
Board of Directors
Our Board of Directors comprises industry veterans and strategic leaders who guide Cohance’s vision and growth. Their expertise spans pharmaceuticals, private equity, and corporate governance, ensuring we remain a trusted partner in health science innovation.
Vivek Sharma
Executive Chairman
Dr. V. Prasada Raju
Managing Director
Pankaj Patwari
Non-Executive Director
K G Ananthakrishnan
Independent Director
Matangi Gowrishankar
Independent Director
Vinod Rao
Independent Director
Pravin Rao
Independent Director
Shweta Jalan
Non-Executive Director
Vinod Padikkal
Non-Executive Director
Jai Shankar Krishnan
Independent Director
Vivek Sharma
Executive Chairman
Vivek Sharma
Executive Chairman
Advisory Board
Our Advisory Board provides specialized insights into emerging therapeutic modalities, regulatory trends, and global market dynamics. Their guidance strengthens our ability to deliver cutting-edge solutions to our partners.
Annaswamy Vaidheesh
Vice-Chair
Venkateswarlu Jasti
Advisor
Stefan Stoffel
Advisor
Abhijit Mukherjee
Advisor
Vivek Sharma
Executive Chairman
Vivek Sharma
Executive ChairmanMr. Vivek Sharma was appointed Executive Chairman of Suven Pharmaceuticals effective September 20, 2024. He is responsible for steering the company’s overall business operations, driving strategic growth initiatives, and enhancing shareholder value. With more than 25 years of global experience spanning the life sciences and financial sectors, Mr. Sharma brings a distinctive combination of expertise in pharmaceutical services, data analytics, and artificial intelligence (AI).
Vivek Sharma
Executive Chairman
Mr. Vivek Sharma was appointed Executive Chairman of Suven Pharmaceuticals effective September 20, 2024.
Dr. V. Prasada Raju
Executive Chairman
Dr. V. Prasada Raju was appointed Managing Director of Suven Pharmaceuticals on September 29, 2023.
Vivek Sharma
Executive Chairman
Mr. Vivek Sharma was appointed Executive Chairman of Suven Pharmaceuticals effective September 20, 2024.
Dr. V. Prasada Raju
Executive Chairman
Dr. V. Prasada Raju was appointed Managing Director of Suven Pharmaceuticals on September 29, 2023.
Vivek Sharma
Executive Chairman
Mr. Vivek Sharma was appointed Executive Chairman of Suven Pharmaceuticals effective September 20, 2024.
Dr. V. Prasada Raju
Executive Chairman
Dr. V. Prasada Raju was appointed Managing Director of Suven Pharmaceuticals on September 29, 2023.
Mr. Vivek Sharma was appointed Executive Chairman of Suven Pharmaceuticals effective September 20, 2024. He is responsible for steering the company’s overall business operations, driving strategic growth initiatives, and enhancing shareholder value. With more than 25 years of global experience spanning the life sciences and financial sectors, Mr. Sharma brings a distinctive combination of expertise in pharmaceutical services, data analytics, and artificial intelligence (AI).
Dr. V. Prasada Raju
Managing Director Dr. V. Prasada Raju
Managing DirectorDr. V. Prasada Raju was appointed Managing Director of Suven Pharmaceuticals on September 29, 2023. He also serves as the CEO and Managing Director of Cohance Lifesciences Ltd.Dr. Raju brings over three decades of comprehensive experience in the pharmaceutical industry, with strong credentials in strategy, operations, scientific affairs, and business development. Previously, he was Executive Director at Granules India Ltd, where he played a pivotal role in shaping growth strategy, managing the product pipeline, leading regulatory and intellectual property functions, and spearheading new business initiatives. He was also instrumental in setting up R&D and Greenfield manufacturing projects.
In his earlier roles, Dr. Raju served on the boards of several key entities, including Granules Omnichem Pvt. Ltd. (Vizag, India), Granules Pharmaceuticals Inc. (Washington, D.C., USA), and USpharma Ltd. (Florida, USA). He spent nearly two decades at Dr. Reddy’s Laboratories (1994–2012), holding senior positions with responsibilities spanning technical, strategic, and operational leadership.
Dr. Raju holds a PhD in Chemistry and a Postgraduate Diploma in Patent Law, and has undergone specialized training in material sciences at IIT, Chicago, USA. He is also an alumnus of the Senior Management Program at the Indian Institute of Management, Calcutta (IIMC).
Dr. Raju’s diverse expertise and leadership acumen position him as a highly respected figure in the pharmaceutical sector.
Other Directorships / Full-time Positions in Body Corporates:
| SI | Name of the Company / Body Corporate | Position |
| 1 | Cohance Lifesciences Limited | Managing Director |
| 2 | Sapala Organics Private Limited | Director |
Pankaj Patwari
Non-Executive Director Pankaj Patwari
Non-Executive DirectorMr. Pankaj Patwari was appointed as a Non-Executive Director of the Company effective 29th September 2023. A Chartered Accountant by training, he also holds an MBA from the Indian Institute of Management, Lucknow.
Mr. Patwari is Managing Director at Advent India PE Advisors Private Limited, where he has led investments in Manjushree Technopack Limited and Bharat Serums and Vaccines Limited. His previous board affiliations include Manjushree Technopack and Gokaldas Intimatewear. Earlier, he worked with Bain Capital for six years, focusing on pharmaceutical and industrial transactions, and spent four years at McKinsey & Company with a concentration on financial services.
Other Directorships / Positions in Body Corporates:
| SI | Name of the Company / Body Corporate | Position |
| 1 | Apollo Healthco Limited | Director |
| 2 | Keimed Private Limited | Director |
| 3 | Advent India PE Advisors Private Limited | Director |
| 4 | Cohance Lifesciences Limited | Non-Executive Chairman |
K G Ananthakrishnan
Independent Director K G Ananthakrishnan
Independent DirectorMr. K G Ananthakrishnan joined as an Independent Director of the Company effective 29th September 2023. He has had a distinguished career spanning over four decades in the pharmaceutical industry.
He served as Director General of the Organization of Pharmaceutical Producers of India (OPPI) and Co-Chair of the Pharma Committee at CII, where he played a key role in shaping public policy. He holds a Masters in Marketing Management from JBIMS, Mumbai, and a Bachelors in Science from Osmania University, Hyderabad. He has also completed executive programs at Wharton Business School and INSEAD. Beginning his career with Novartis India in 1976, he held senior roles at Pharmacia, Pfizer, and Fulford (India). As VP and MD – South Asia Region for MSD, he led a transformation into a high-growth company.
Other Directorships / Positions in Body Corporates:
| SI | Name of the Company / Body Corporate | Position |
| 1 | Gujarat Themis Biosyn Ltd | Independent Director |
| 2 | Rubicon Research Limited | Independent Director |
| 3 | Sapala Organics Private Limited | Independent Director |
| 4 | Punjab National Bank | Non-Executive Chairman |
| 5 | Mango Cancer Care Foundation | Non-Executive Director |
Matangi Gowrishankar
Independent Director Matangi Gowrishankar
Independent DirectorMs. Matangi Gowrishankar was appointed as an Independent Director of the Company effective 29th September 2023. A Strategic Advisor and Certified Coach, she has 40+ years of global leadership experience.
Previously, she was the Global Head of Capability Development at BP, where she drove leadership and talent transformation. Ms. Gowrishankar has collaborated closely with senior leaders across industries, offering expertise in contemporary leadership, digital transformation, and culture-building for sustainable growth.
Other Directorships / Positions in Body Corporates:
| SI | Name of the Company / Body Corporate | Position |
| 1 | Greenlam Industries Limited | Independent Director |
| 2 | Cyient Limited | Independent Director |
| 3 | Akums Drugs and Pharmaceuticals Limited | Independent Director |
| 4 | Gujarat Pipavav Port Limited | Independent Director |
| 5 | IDFC First Bank Limited | Independent Director |
| 6 | Premium Transmission Limited | Director |
| 7 | Premium Motion Private Limited | Director |
| 8 | Intellecap Advisory Services Private Limited | Director |
| 9 | Anudip Foundation for Social Welfare | Director |
| 10 | Cyient Europe Limited | Director |
Vinod Rao
Independent Director Vinod Rao
Independent DirectorMr. Vinod Rao was appointed as an Independent Director effective 29th September 2023. He is also a Director at Eureka Forbes. With over 35 years of experience, Mr. Rao has held senior roles at Diageo, PepsiCo, and ICI across consumer goods, industrial products, and consumer durables.
His leadership spans global markets including India, Southeast Asia, China, the UK, and Europe, giving him wide-ranging business and operational exposure.
Other Directorships / Positions in Body Corporates:
| SI | Name of the Company / Body Corporate | Position |
| 1 | Eureka Forbes Limited | Independent Director |
| 2 | Cohance Lifesciences Limited | Independent Director |
| 3 | Isha Foundation, UK | Designated Partner |
Pravin Rao
Independent Director Pravin Rao
Independent DirectorMr. Pravin Rao joined the Company as an Independent Director on 9th November 2023. A graduate in Electrical Engineering from Bangalore University, Mr. Rao has over 35 years of experience in the technology sector.
He began his career at Infosys in 1986 and rose to become Chief Operating Officer and Board Member before his retirement in December 2022. He currently serves as an Independent Director on the boards of several leading firms in financial services and health-tech.
Other Directorships / Positions in Body Corporates:
| SI | Name of the Company / Body Corporate | Position |
| 1 | Sowparnika Retail Private Limited | Independent Director |
| 2 | Computer Age Management Services Limited | Independent Director |
| 3 | Zensar Technologies Limited | Independent Director |
| 4 | Indegene Limited | Independent Director |
| 5 | Axis Finance Limited | Independent Director |
Shweta Jalan
Non-Executive Director Shweta Jalan
Non-Executive DirectorMs. Shweta Jalan joined as a Non-Executive Director of the Company on 9th November 2023. She has been Managing Director at Advent India PE Advisors since 2009.
She has prior experience at ICICI Venture and Ernst & Young. Ms. Jalan has led transactions across industrials, media, IT/BPO, and business services. She advises on investment structuring, growth strategies, and successful exits.
Other Directorships / Positions in Body Corporates:
| SI | Name of the Company / Body Corporate | Position |
| 1 | Sowparnika Retail Private Limited | Director |
| 2 | Yes Bank Limited | Non-Executive – Non-Independent Director |
| 3 | Modenik Lifestyle Private Limited | Director |
| 4 | Cohance Lifesciences Limited | Non-Executive – Non-Independent Director |
| 5 | Manjushree Technopack Limited | Director |
Vinod Padikkal
Non-Executive Director Vinod Padikkal
Non-Executive DirectorMr. Vinod Padikkal is a Senior Portfolio Manager at the Abu Dhabi Investment Authority (ADIA), overseeing private equity investments in India and Southeast Asia. He joined ADIA in 2021.
He previously held roles at Advent International, Bain Capital, and Bain & Company, where he focused on investment strategy and operational improvement. He holds a B.Tech in Computer Science from Cochin University and an MBA from IIM Ahmedabad.
Other Directorships / Positions in Body Corporates:
| SI | Name of the Company / Body Corporate | Position |
| 1 | Nil | Nil |
Jai Shankar Krishnan
Independent Director Jai Shankar Krishnan
Independent DirectorMr. Jai Shankar Krishnan has been driving growth for Danaher Corporation in High Growth Markets since 2019. He began his tenure at Danaher in 2008 as President and CEO – India, and later expanded his leadership to Southeast Asia and other global regions.
Prior to Danaher, he held senior positions at PerkinElmer, Novartis, GSK, and began his career at Hindustan Unilever. Mr. Krishnan holds an MBA from BIT, is a Harvard Business School alumnus, and is a certified coach and Lean Six Sigma Master Black Belt.
Other Directorships / Positions in Body Corporates:
| SI | Name of the Company / Body Corporate | Position |
| 1 | Wellness Forever Medicare Limited | Director |
| 2 | Lineology Private Limited | Director |
| 3 | Arkanova LLP | Trustee, Board of Trustees |
Executive Leadership Team
The Executive Leadership Team drives operational excellence and strategic execution across Cohance’s global operations. With deep experience in life sciences, CDMO growth, and regulatory compliance, they lead with agility and purpose.
The Executive Leadership Team steers operational excellence and strategic execution across Cohance’s global footprint. With extensive experience spanning life sciences, the pharmaceutical sector, and the CDMO industry—including regulatory compliance and business scaling—they lead with agility, vision, and purpose.
Vivek Sharma
Executive Chairman
Mr. Vivek Sharma was appointed Executive Chairman of Suven Pharmaceuticals effective September 20, 2024.
Dr. V. Prasada Raju
Executive Chairman
Dr. V. Prasada Raju was appointed Managing Director of Suven Pharmaceuticals on September 29, 2023.
Vivek Sharma
Executive Chairman
Mr. Vivek Sharma was appointed Executive Chairman of Suven Pharmaceuticals effective September 20, 2024.
Dr. V. Prasada Raju
Executive Chairman
Dr. V. Prasada Raju was appointed Managing Director of Suven Pharmaceuticals on September 29, 2023.
Vivek Sharma
Executive Chairman
Mr. Vivek Sharma was appointed Executive Chairman of Suven Pharmaceuticals effective September 20, 2024.
Dr. V. Prasada Raju
Executive Chairman
Dr. V. Prasada Raju was appointed Managing Director of Suven Pharmaceuticals on September 29, 2023.
Sudhir Kumar Singh, PhD
Chief Executive Officer Sudhir Kumar Singh, PhD
Chief Executive OfficerAppointed: 29 September 2023
Dr. Sudhir Kumar Singh is the Chief Executive Officer of the Company. A distinguished scientist and industry leader, he holds a PhD in Medicinal Chemistry from the Central Drug Research Institute, one of India’s premier research institutions. He completed his postdoctoral fellowship in the USA and served as a faculty member at Rutgers University, New Jersey.
With over three decades of experience in the pharmaceutical and biotech industry, Dr. Singh has held leadership roles including Chief Operating Officer at Aragen Life Sciences Ltd., where he led India’s largest Contract Development and Manufacturing Organization (CDMO) with a team of over 2,000 scientists. His strategic vision and deep expertise in drug discovery and development have consistently driven organizational growth and innovation.
A pioneer in his field, Dr. Singh has contributed significantly to the advancement of novel therapies through research excellence and patented innovations.
Gaurav Bahadur
Chief Human Resources Officer Gaurav Bahadur
Chief Human Resources OfficerAppointed: 29 September 2023
Mr. Gaurav Bahadur is the Chief Human Resources Officer of the Company, responsible for leading the people strategy and HR functions.
He brings a strong track record in shaping performance-driven cultures across leading organizations such as Vodafone Essar, Yahoo! India, Philips India, and Sanofi India—where he led key HR transformations. Gaurav holds a Masters degree in Personnel Management from the Symbiosis Institute of Business Management and a Bachelors degree in Chemistry from St. Xavier’s College, Mumbai.
His expertise in driving strategic human capital initiatives plays a key role in aligning talent development with the company’s business goals.
Himanshu Agarwal
Chief Financial Officer Himanshu Agarwal
Chief Financial OfficerAppointed: 2 January 2024
Mr. Himanshu Agarwal is the Chief Financial Officer of the Company and oversees Finance, IT, Legal, Secretarial, and Investor Relations.
He brings 29 years of professional experience, having held senior roles at ICI India, AstraZeneca Pharma, Akzo Nobel India, Huhtamaki Oyj, and Bennett, Coleman & Co. Ltd. Himanshu’s deep expertise spans finance, M&A, investor relations, business strategy, and technology enablement across sectors including pharmaceuticals, packaging, media, chemicals, and coatings.
A rank-holder Chartered Accountant, Company Secretary, and Cost and Management Accountant, Himanshu has led numerous strategic initiatives including finance transformation, profit turnaround, value chain optimization, and M&A integrations. He has also enabled enterprise-wide technology adoption—from ERP systems to BOTs—and was awarded ‘Best CFO’ by the Institute of Chartered Accountants of India.
K. Nagendra Babu, PhD
Chief Quality and Compliance Officer K. Nagendra Babu, PhD
Chief Quality and Compliance OfficerDr. K. Nagendra Babu brings over 25 years of rich experience across Finished Dosage Forms and APIs in the areas of Global Audit and Compliance, Vendor and Third-Party Management, QA, QC, DQA, CQA, and manufacturing.
He has held leadership roles in top pharma companies including Mylan (Viatris), Gravity Pharmaceuticals, Granules India, GSK Pharmaceuticals, Dr. Reddy’s Laboratories, and Aurobindo Pharma. Dr. Babu holds a PhD in Chemistry and has undergone extensive training in regulatory compliance and GxP audits.
He works closely with Quality Operations, Regulatory Affairs, and the broader Operations team to implement industry-leading quality and compliance systems and standards.
Advisory Board
Our Advisory Board provides specialized insights into emerging therapeutic modalities, regulatory trends, and global market dynamics. Their guidance strengthens our ability to deliver cutting-edge solutions to our partners.
Vivek Sharma
Executive Chairman
Mr. Vivek Sharma was appointed Executive Chairman of Suven Pharmaceuticals effective September 20, 2024.
Dr. V. Prasada Raju
Executive Chairman
Dr. V. Prasada Raju was appointed Managing Director of Suven Pharmaceuticals on September 29, 2023.
Vivek Sharma
Executive Chairman
Mr. Vivek Sharma was appointed Executive Chairman of Suven Pharmaceuticals effective September 20, 2024.
Dr. V. Prasada Raju
Executive Chairman
Dr. V. Prasada Raju was appointed Managing Director of Suven Pharmaceuticals on September 29, 2023.
Vivek Sharma
Executive Chairman
Mr. Vivek Sharma was appointed Executive Chairman of Suven Pharmaceuticals effective September 20, 2024.
Dr. V. Prasada Raju
Executive Chairman
Dr. V. Prasada Raju was appointed Managing Director of Suven Pharmaceuticals on September 29, 2023.
Annaswamy Vaidheesh
Vice-Chair Annaswamy Vaidheesh
Vice-ChairMr. Annaswamy Vaidheesh is a seasoned business leader with over 35 years of experience across some of the most admired Fortune 100 companies in the healthcare and FMCG sectors, including Johnson & Johnson, Pfizer, and GSK. He brings deep expertise in general management, market creation, and leadership development across multi-cultural and multi-market environments in the Asia-Pacific region.
He has served as President of the Organization of Pharmaceutical Producers of India (OPPI) and chaired several committees of leading industry bodies. Recognized by organizations such as The Economic Times for his leadership excellence, he has also served as an Operating Partner with Advent International.
Venkateswarlu Jasti
Advisor Venkateswarlu Jasti
AdvisorMr. Venkateswarlu Jasti holds postgraduate degrees in Pharmacy from Andhra University, Visakhapatnam, and St. John’s University, New York, specializing in Industrial Pharmacy.
A pioneer of the CRAMS business model in India, Mr. Jasti founded Suven Pharma Ltd. and Suven Life Sciences Ltd., leading their growth since inception in 1989. Under his leadership, Suven Life Sciences developed a robust discovery pipeline, including SUVN-502 (Phase 3 trials in the US for Alzheimer’s-related agitation) and SUVN-G3031 (Phase 2 completed for narcolepsy).
He has played instrumental roles in forming the AP Chief Minister’s Task Force for Pharma, establishing Pharma City in Visakhapatnam, and launching PHARMEXCIL. He has held leadership positions in industry associations such as the Indian Pharmaceutical Association and the Bulk Drug Manufacturers Association of India.
Stefan Stoffel
Advisor Stefan Stoffel
AdvisorAppointed: October 2023
Mr. Stefan Stoffel is an accomplished operations leader with over 35 years of experience in production engineering, plant operations, and supply chain management. He holds an engineering degree from Lucerne University of Applied Sciences and Arts, Switzerland.
Formerly the COO of Lonza, Mr. Stoffel has held key positions including Head of Lonza Pharma & Biotech Strategic Growth Investments and Ibex Solutions, and General Manager of Lonza’s Chemical Operations Business Unit. He brings unmatched experience in managing complex global operations and driving strategic growth across the life sciences sector.
Abhijit Mukherjee
Advisor Abhijit Mukherjee
AdvisorAppointed: October 2023
Mr. Abhijit Mukherjee is a chemical engineer from IIT Kharagpur and brings decades of operational and leadership experience in the pharmaceutical and chemical industries.
He served Dr. Reddy’s Laboratories for over 15 years, most recently as Chief Operating Officer from 2014 until his retirement in 2018. His earlier stints include leadership roles at Hindustan Unilever (13 years) and Atul Ltd. (9 years). He currently serves on the boards of Bharat Serums and Vaccines Ltd., ZCL Chemicals Ltd., and ICE, Milan (Italy).
.
William Downie
Advisor William Downie
AdvisorMr. Will Downie is a globally respected biopharma services executive and two-time CDMO CEO with a proven track record in commercial transformation and value creation.
As CEO of Vectura, he repositioned the company as a leader in inhalation CDMO, doubling its value and leading its strategic sale. At Argenta, he built the world’s top CRO/CDMO in animal health under KKR ownership. As CCO of Catalent, he helped drive its evolution into a top-three global CDMO and supported its transition to a NYSE-listed company.
Currently a Strategic Advisor to Boards and an Operating Partner with a leading private equity firm, he focuses on commercial strategy, transformation, and leadership in the pharma and CDMO industries.
Mark Peacock
Advisor Mark Peacock
AdvisorMr. Mark Peacock is a seasoned global operations leader with 30 years of experience across the AgChem, specialty chemicals, and pharmaceutical industries.
He spent over a decade as a member of the Executive Team at Syngenta, where he led global operations across supply, manufacturing, technology, HR, IS, and marketing. Known for driving business transformation and productivity, he brings deep expertise in systems thinking, change management, and operational excellence.
Bhasker Iyer
Advisor Bhasker Iyer
AdvisorMr. Bhasker Iyer is a strategic business leader with over four decades of experience in pharmaceuticals and healthcare. He has held leadership roles across AstraZeneca (Asia-Pacific), Wockhardt, Nicholas Piramal, ICI Pharmaceuticals, and Glaxo India. As Vice President at Abbott, he oversaw sales, manufacturing, and R&D for India’s largest healthcare MNC.
Currently an Operating Partner at Advent and Board Director for Quadria Capital, Mr. Iyer also serves as an Independent Director on the boards of RPG Life Sciences, Cohance Lifesciences, Themis Medicare, and Corona Remedies, contributing to strategic direction and value creation across the healthcare ecosystem.
Empowering People
Our diverse team is at the core of our success. We cultivate an inclusive, supportive workplace by:
- Talent Development: Providing robust training and career growth opportunities to nurture expertise and innovation.
- Well-Being Initiatives: Prioritizing employee health, safety, and satisfaction through comprehensive programs.
- Diversity and Inclusion: Fostering an equitable environment where all voices are valued.
Our Social Accountability Policy ensures respect for human rights and a thriving workplace.
Building Trust
Building Trust
Trust underpins our partnerships. We uphold ethical governance through:
- Transparent Decision-Making: Ensuring accountability with rigorous oversight and audits.
- Ethical Practices: Adhering to our Anti-Bribery and Anti-Corruption Policy.
- Stakeholder Engagement: Aligning strategies with partner and community expectations.
Our Business Continuity and Information Security Policies ensure reliability and care in all operations.
Collaborating for Community Impact
We engage with communities to drive positive change through:
- Education and Health: Supporting programs to enhance access to education and healthcare.
- Safe Drinking Water: Investing in clean water initiatives to improve public health.
- Economic Stability: Partnering with local organizations to create economic opportunities.
These efforts align with our mission to bring people and science together for a healthier world.
Sustainability in Action
Sustainability is embedded in every stage of our operations. We integrate innovation and responsibility to deliver cutting-edge, sustainable solutions:
- Energy-Efficient Processes: Adopting technologies to reduce energy consumption and waste.
- Life Cycle Assessments (LCA): Evaluating product environmental impacts to make informed, sustainable decisions.
- Green Chemistry: Minimizing hazardous substances in development to ensure eco-friendly pharmaceuticals.
- Policy Implementation: Our Pharmaceuticals in the Environment and Product End of Life Policies reduce environmental impact while maintaining quality.
- Community Engagement: Initiatives like providing safe drinking water and supporting education amplify our social impact.
By prioritizing customer health, safety, and environmental responsibility, we create lasting value for our partners and the planet.
Our ESG Aspirations
Cohance is committed to a sustainable future with ambitious goals:
- Net-Zero Emissions by 2050: Focusing on decarbonization, renewable energy, and resource efficiency, aligned with Science-Based Targets (SBTi).
- Environmental Sustainability: Enhancing green practices through sustainable procurement and biodiversity protection.
- Social Impact: Expanding community engagement in health, sanitation, and water access, while supporting economic development through CSR initiatives.
- UN SDG Alignment: Contributing to goals like Good Health and Well-Being, Clean Water and Sanitation, and Responsible Consumption and Production.
- Ethical Governance: Strengthening transparency, ethics, and responsible sourcing through global initiatives like the Pharmaceutical Supply Chain Initiative (PSCI).
At Cohance, ESG is our promise to go above and beyond, shaping a sustainable future for health science through passion, expertise, and unwavering responsibility.
History
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
Lorem ipsum
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
Experience
Our great team of more than 1400 software experts.
Quick Support
We’ll help you test bold new ideas while sharing your.
Leadership Team
John Smith
CEO
Emma London
Co-Founder
Jessica Brown
Managing Director
Christine Eve
Designer
Sustainability
ESG
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
EHS
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
Quality & Compliance
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
We deal With The Aspects Of Professional IT Services
About usEngitech is the partner of choice for many of the world’s leading enterprises, SMEs and technology challengers. We help businesses elevate their value through custom software development, product design,
Experience
Our great team of more than 1400 software experts.
Quick Support
We’ll help you test bold new ideas while sharing your.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna.
440
employees from around the world
+
640
happy clients from largest corporations
+
0
offices in 6 counties worldwide
We deal With The Aspects Of Professional IT Services
About usEngitech is the partner of choice for many of the world’s leading enterprises, SMEs and technology challengers. We help businesses elevate their value through custom software development, product design,
UI/UX Design
95%
App Development
82%
Business Growth
90%
Technology Solution
80%
Science & Technology
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
John Smith
A leading Company
Here’s What’s Happening
From our blog
Title
Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Title
Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Title
Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Title
Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Title
Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.